Search
Atopic Dermatitis Clinical Trials
A listing of 56 Atopic Dermatitis clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 56
There are currently 56 active clinical trials seeking participants for Atopic Dermatitis research studies. The states with the highest number of trials for Atopic Dermatitis participants are California, Florida, Texas and Ontario.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
A Study Evaluating APG777 in Atopic Dermatitis
Recruiting
This is a two-part study that will evaluate the safety and efficacy of APG777 in participants with moderate-to-severe Atopic Dermatitis (AD). Part A (Proof-of-concept) and Part B (Dose-regimen Finding) will evaluate the safety and efficacy of various induction and maintenance dose regimens of APG777 compared to placebo. The study duration for any individual participant will be up to 106 weeks which includes: screening, induction, maintenance, and post-treatment follow-up periods. Participants ra... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: Investigational Site #14, Fountain Valley, California +79 locations
Conditions: Atopic Dermatitis
Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis
Recruiting
This is a multinational, multicenter, double-blind, placebo-controlled, parallel-group Phase 2, 4-arm study in adult participants with moderate to severe AD who are inadequately controlled with topical therapies or for whom such topical therapies are inadvisable and who are candidates for systemic therapy.
Participants will be randomized to receive SAR444656 dose 1, dose 2, dose 3 or matching placebo.
Participants who meet inclusion/exclusion criteria will be stratified for randomization by se... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: Clear Dermatology & Aesthetics Center- Site Number : 8400003, Scottsdale, Arizona +34 locations
Conditions: Atopic Dermatitis
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
Recruiting
This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
06/11/2025
Locations: Novartis Investigative Site, Birmingham, Alabama +10 locations
Conditions: Atopic Dermatitis
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
Recruiting
The purpose of the study is to assess the efficacy and safety of ruxolitinib cream in children and adolescents (6 to \<18 Years Old) with moderate atopic dermatitis.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
06/11/2025
Locations: Clinical Research Center of Alabama, Birmingham, Alabama +91 locations
Conditions: Atopic Dermatitis
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
Recruiting
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study aims to provide data on the efficacy and safety of upadacitinib at different doses in adult participants with moderate to severe AD.
Upadacitinib is an approved drug for the treatment of moderate to severe atopic dermatitis (AD). This stud... Read More
Gender:
ALL
Ages:
Between 18 years and 63 years
Trial Updated:
06/10/2025
Locations: Clinical Trials Institute - Northwest Arkansas /ID# 267290, Fayetteville, Arkansas +93 locations
Conditions: Atopic Dermatitis
A Study of How Safe Abrocitinib (CIBINQO) is in Pregnant Women and Their Offspring
Recruiting
The purpose of this observational study is to learn about the safety of abrocitinib (CIBINQO) in pregnant women and the offspring.
The study is seeking participants who:
* Are currently or recently pregnant
* Receive at least one dose of CIBINQO at any time during pregnancy or prior to pregnancy OR have a diagnosis of moderate-to-severe atopic dermatitis
All participants in this study will receive treatment according to routine care, as this is an observational study. The exposed group will c... Read More
Gender:
FEMALE
Ages:
0 years and above
Trial Updated:
06/10/2025
Locations: Pfizer, New York, New York
Conditions: Atopic Dermatitis
Studies of Skin Microbes in Healthy People and in People With Skin Conditions
Recruiting
This study will examine microbes (e.g., bacteria, fungi, viruses) that live on human skin and how microbes contribute to health and disease. It will analyze healthy human skin and how the these microorganisms might change in patients with atopic dermatitis (AD), a skin condition also known as eczema.
Healthy volunteers, as well as patients with moderate to severe eczema (AD), between 2 and 40 years of age may be eligible for this study.
We also wish to enroll children and adults aged 2-40 who... Read More
Gender:
ALL
Ages:
Between 2 years and 100 years
Trial Updated:
06/07/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Atopic Dermatitis, Eczema
ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis
Recruiting
This study evaluates ATI-045 versus placebo in patients with Moderate-to-Severe Atopic Dermatitis.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/05/2025
Locations: Aclaris Study Site, Bryant, Arkansas +19 locations
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Atopic Dermatitis
Recruiting
The purpose of this study is to assess the efficacy and safety of RO7790121 in participants with moderate to severe atopic dermatitis (AD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: Dermatology Research Associate, Los Angeles, California +12 locations
Conditions: Atopic Dermatitis
Skin Microbial Ecology in Atopic Dermatitis
Recruiting
Everybody's skin has bacteria that normally lives on it. Previous research has shown that people with eczema (or atopic dermatitis \[AD\]) have much higher concentrations of a certain bacteria (S. aureus), especially when their disease is active but little is known about the role that this bacteria plays in psoriasis (i.e. disease severity, biomarkers and skin barrier function). The overarching purpose of this longitudinal study is to understand how the abundance of skin S. aureus (and several c... Read More
Gender:
ALL
Ages:
13 years and above
Trial Updated:
06/02/2025
Locations: University of Rochester Medical Center, Rochester, New York
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis
Recruiting
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. The purpose of this study is to evaluate the clinical efficacy and safety of single therapies and/or combination therapies for moderate to severe AD through multiple substudies.
This study will consist of multiple sub-studies, Sub-Study 1 will have a randomized, placebo controlled period 1 followed by a lutikizumab treatment period 2 enrolling 80 participants at a 1 to 1 ratio.
In Sub-... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Peak Dermatology Aesthetics and Wellness Fountain Hills /ID# 272550, Fountain Hills, Arizona +21 locations
Conditions: Atopic Dermatitis
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
Recruiting
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Topical therapies applied over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study compares upadacitinib to dupilumab in pediatric participants with moderate to severe AD who are candidates for systemic therapy. Adverse events and change in the disease activity will be assessed.
Upadacitinib is an approved drug... Read More
Gender:
ALL
Ages:
Between 2 years and 11 years
Trial Updated:
05/30/2025
Locations: Applied Research Center Of Arkansas /ID# 268547, Little Rock, Arkansas +123 locations
Conditions: Atopic Dermatitis
1 - 12 of 56